<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03207425</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 305-003</org_study_id>
    <nct_id>NCT03207425</nct_id>
  </id_info>
  <brief_title>A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel Group, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of EDP 305 in Subjects With Varying Degrees of Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to characterize the pharmacokinetics as well as safety and tolerability of a
      single oral dose of EDP-305 in subjects with mild and moderate hepatic impairment compared to
      matched healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Actual">September 19, 2017</completion_date>
  <primary_completion_date type="Actual">September 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of EDP 305</measure>
    <time_frame>From pre-dose on Day 1 until 216 hour post-dose (Day 10)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of EDP 305</measure>
    <time_frame>From pre-dose on Day 1 until 216 hour post-dose (Day 10)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of EDP 305</measure>
    <time_frame>From pre-dose on Day 1 until 216 hour post-dose (Day 10)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of EDP 305</measure>
    <time_frame>From pre-dose on Day 1 until 216 hour post-dose (Day 10)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety measured by adverse events, physical exams, vital signs, 12-lead electrocardiograms (ECGs) and clinical lab results (including chemistry, hematology, and urinalysis).</measure>
    <time_frame>From Screening up to Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>NASH</condition>
  <arm_group>
    <arm_group_label>Mild hepatic impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching healthy control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy control group will be matched with the hepatically impaired population with respect to age, sex and BMI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP 305</intervention_name>
    <description>Each subject will receive a single dose of EDP 305 on Day 1.</description>
    <arm_group_label>Mild hepatic impairment group</arm_group_label>
    <arm_group_label>Moderate hepatic impairment group</arm_group_label>
    <arm_group_label>Matching healthy control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand and willing to sign the ICF and able to comply with the study
             restrictions

          -  Adult male or female subjects age 18 to 75 years, inclusive, at the time of informed
             consent

          -  Female subjects must be non-childbearing potential

        Additional criteria for hepatically impaired subjects

          -  Confirmed diagnosis of cirrhosis due to parenchymal liver disease

          -  Stable hepatic impairment, defined as no clinically significant change in disease
             status, as judged by the Investigator

        Exclusion Criteria:

          -  Clinically relevant abnormal medical history, abnormal findings on physical
             examination, vital signs, ECG, or laboratory tests at Screening that the Investigator
             judges as likely to interfere with the objectives of the trial or the safety of the
             volunteer except for conditions associated with hepatic impairment in subjects with
             compromised hepatic function

          -  Clinically significant renal disease

        Additional criteria for hepatically impaired Subjects

          -  History of esophageal bleeding within the last 3 months prior to study drug
             administration

          -  Severe hepatic encephalopathy (Grade &gt;2) or degree of central nervous system (CNS)
             impairment

          -  History of liver transplantation

          -  Presence of Hepatocellular Carcinoma, or suspicion of Hepatocellular Carcinoma based
             on Investigator's judgment

          -  Hepato-renal or hepato-pulmonary syndrome

          -  Prior placement of a portosystemic shunt

          -  Spontaneous bacterial peritonitis currently or within the last 6 months

          -  Hospitalization within the last 2 months related to cirrhosis

          -  Advanced ascites and ascites which require emptying and albumin supplementation, as
             judged by the Investigator

          -  Hemoglobin concentration &lt; 10.0 g/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>American Research Corporation at The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceuticals Research Associates</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit SRO</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

